| Similar Articles |
|---|
 |
Managed Care
November 2004
Martin Sipkoff |
OTC Status for Low-Dose Lovastatin Would Have Widespread Implications The FDA stands poised to approve OTC low-dose statins, following a similar change in United Kingdom.   |
The Motley Fool
November 27, 2007
Brian Orelli |
Second Chance for Merck's MEVACOR Merck licenses the rights to an over-the-counter version of its cholesterol-lowering drug MEVACOR to GlaxoSmithKline, but the deal is far from done. Investors, take note. |
The Motley Fool
December 14, 2007
Brian Orelli |
Panel Kills Merck's Hope of OTC Status An FDA advisory panel isn't convinced that Merck's cholesterol-lowering drug MEVACOR deserves OTC status. |
The Motley Fool
May 20, 2011
Brian Orelli |
Abbott Hits a Triple Not a home run, but Trilipix will likely stay on the market. |
The Motley Fool
April 29, 2008
Brian Orelli |
Merck's Recovery Flushed Down Merck's best hope at recovery fails approval by the FDA. |
The Motley Fool
November 3, 2009
Brian Orelli |
A Little Distracted, Are You, Merck? The FDA rejects its latest application. |
BusinessWeek
July 21, 2003
Amy Barrett |
A Bare-Knuckle Battle over Cholesterol Drugs If AstraZeneca's Crestor is approved, rivals' stepped-up pitches will focus on safety |
The Motley Fool
June 26, 2008
Brian Orelli |
The FDA's Latest Victim Merck fails to get its Gardasil vaccine approved to treat older women. |
Pharmaceutical Executive
January 1, 2006
Kenneth I. Kaitin |
Opinion: Memo to von Eschenbach FDA's acting commissioner has an opportunity to clarify a lot of misconceptions about the agency's role in regulating drug safety. His first order of business should be to explain exactly what FDA doesn't do. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
Global Services
May 5, 2008
Adyasha Sinha |
The U.S. Gains Momentum as an Outsourcing Hub With more and more U.K. firms plunging into offshoring, their next-door neighbor, the U.S., gains brownie points as an outsourcing destination |
National Defense
September 2009
Grace V. Jean |
U.K. Military Spending on the Rise, Says MOD Official Quentin Davies, U.K. minister for defense equipment and support, categorically denied reports about upcoming budget cuts in U.K. military programs. |
CIO
March 15, 2006
Allan Holmes |
Rx for Risk As it revamps its workflow processes, the FDA is relying on technology to reduce the risk that unsafe substances will get into the market. |
The Motley Fool
January 27, 2004
Jeff Hwang |
Merck in the Balance These are troubled times for Merck. Restructuring charges, Zocor sales woes, and a new distribution program hamper earnings. |
The Motley Fool
December 16, 2008
Brian Orelli |
Doubling Up on Triple Lipid Drugs The Food and Drug Administration gave Abbott Lab's TriLipix the thumbs-up, approving it for use by itself or with statins. |
Information Today
October 18, 2010 |
Full-Text Doctoral Dissertations on Middle East and Islamic Studies Available Free The British Library's partnership project with the Chicago-based Center for Research Libraries has now released digitized copies of 400 U.K. Ph.D. theses on Middle Eastern and Islamic studies. |
The Motley Fool
November 22, 2010
Brian Orelli |
Let's Call It a Partial Victory Merck's Vytorin works better than a placebo. Unfortunately, it may be too little and too late to do anything about the sales cut that Vytorin has taken over the past few years. |
Financial Planning
November 1, 2008
David E. Adler |
The Yanks Are Coming! The credit crunch in the United States is usually blamed for the sudden and severe economic contraction in the United Kingdom, lamented as the worst economic crisis to face Britain in 60 years. But this hostility does not extend to the U.S. financial planning industry. |
Pharmaceutical Executive
November 1, 2011
Roger L. Williams |
Spotlight on OTCs With OTCs challenging traditional approaches to quality, new opportunities are arising to support industry innovation and advance public health. |
